Spitzoid melanoma with histopathological features of ALK gene rearrangement exhibiting ALK copy number gain: a novel mechanism of ALK activation in spitzoid neoplasia

Spitzoid neoplasms pose diagnostic difficulties because their morphology is not consistently predictive of their biological potential. Recent advances in the molecular characterization of these tumours provides a framework by which they can now begin to be categorized. In particular, spitzoid lesions with ALK rearrangement have been specifically associated with a characteristic plexiform growth pattern of intersecting fascicles of amelanotic spindled melanocytes. We report the case of an 87‐year‐old man with a 3‐cm nodule on his mid‐upper back comprised of an intradermal proliferation of fusiform amelanotic melanocytes arranged in intersecting fascicles with occasional peritumoral clefts. Immunohistochemical studies demonstrated diffuse, strong expression of SOX10 and S100 by the tumour cells and diffuse, weak‐to‐moderate cytoplasmic positivity for anaplastic lymphoma kinase (ALK), suggestive of ALK rearrangement. Fluorescence in situ hybridization revealed no ALK rearrangements but instead revealed at least three intact ALK signals in 36% of the tumour cells, confirming ALK copy number gain. To our knowledge, this is the first reported case of a plexiform spitzoid neoplasm exhibiting ALK copy number gain instead of ALK rearrangement. This case suggests that ALK copy number gain is a novel mechanism of ALK activation but with the same characteristic histopathological growth pattern seen among ALK‐rearranged spitzoid neoplasms.

[1]  G. Boland,et al.  Atypical ALK‐positive Spitz tumors with 9p21 homozygous deletion: Report of two cases and review of the literature , 2018, Journal of cutaneous pathology.

[2]  Jennifer D. Hintzsche,et al.  ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms , 2017, Molecular Cancer Therapeutics.

[3]  A. Reuben,et al.  Toward a Molecular-Genetic Classification of Spitzoid Neoplasms. , 2017, Clinics in laboratory medicine.

[4]  Pedram Gerami,et al.  A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms , 2017, The American journal of surgical pathology.

[5]  R. Halaban,et al.  Spitz nevi and Spitzoid melanomas - Exome sequencing and comparison to conventional melanocytic nevi and melanomas , 2016, Modern Pathology.

[6]  Jonathan A. Busam,et al.  Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation , 2016, The American journal of surgical pathology.

[7]  W. Sanger,et al.  Section E6.5–6.8 of the ACMG technical standards and guidelines: chromosome studies of lymph node and solid tumor–acquired chromosomal abnormalities , 2016, Genetics in Medicine.

[8]  G. Botti,et al.  A new look at the ALK gene in cancer: copy number gain and amplification , 2016, Expert review of anticancer therapy.

[9]  K. Busam,et al.  Spitz Tumors , 2016, International journal of surgical pathology.

[10]  Gary K. Schwartz,et al.  Alternative transcription initiation leads to expression of a novel ALK isoform in cancer , 2015, Nature.

[11]  I. Yeh,et al.  Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions , 2015, The American journal of surgical pathology.

[12]  Yuan Qi,et al.  Clinical actionability enhanced through deep targeted sequencing of solid tumors. , 2015, Clinical chemistry.

[13]  L. Cerroni,et al.  Clinical and Pathologic Findings of Spitz Nevi and Atypical Spitz Tumors With ALK Fusions , 2014, The American journal of surgical pathology.

[14]  B. B. Weitner,et al.  Histomorphologic Assessment and Interobserver Diagnostic Reproducibility of Atypical Spitzoid Melanocytic Neoplasms With Long-term Follow-up , 2014, The American journal of surgical pathology.

[15]  Funda Meric-Bernstam,et al.  Bias from removing read duplication in ultra-deep sequencing experiments , 2014, Bioinform..

[16]  Iwei Yeh,et al.  Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.

[17]  G. Mills,et al.  CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features , 2013, PloS one.

[18]  R. Palmer,et al.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology , 2013, Nature Reviews Cancer.

[19]  D. Elder,et al.  Outcomes of Atypical Spitz Tumors With Chromosomal Copy Number Aberrations and Conventional Melanomas in Children , 2013, The American journal of surgical pathology.

[20]  H. Kearney,et al.  Section E9 of the American College of Medical Genetics technical standards and guidelines: Fluorescence in situ hybridization , 2011, Genetics in Medicine.

[21]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[22]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[23]  R. Barnhill The Spitzoid lesion: rethinking Spitz tumors, atypical variants, ‘Spitzoid melanoma’ and risk assessment , 2006, Modern Pathology.

[24]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[25]  W. Cavenee,et al.  Point mutations can inactivate in vitro and in vivo activities of p16INK4a/CDKN2A in human glioma , 1997, Oncogene.

[26]  Claude-Alain H. Roten,et al.  Theoretical and practical advances in genome halving , 2004 .

[27]  W. McLaren,et al.  Bioinformatics Applications Note Databases and Ontologies Deriving the Consequences of Genomic Variants with the Ensembl Api and Snp Effect Predictor , 2022 .